Holostem Terapie Avanzate s.r.l.   Report issue

For profit Phase 2
Founded: Modena Italy (2008)

Organization Overview

First Clinical Trial
2017
NCT02984085
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Holostem Terapie Avanzate s.r.l.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epidermolysis Bullosa (Phase 2)

Epidermolysis Bullosa Dystrophica (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2